Acne Vulgaris Treatment Market Competitive Analysis, Regional Outlook and Forecast Analysis during 2022-2028
Acne Vulgaris Treatment Market |
Blackheads, whiteheads, papules,
and pustules on the face, neck, back, and chest are the main features of the
common skin condition acne vulgaris. Although frequently seen in adolescents,
it can also affect adults. Acne can be divided into three categories: mild,
moderate, and severe. Sebaceous glands under the skin produce too much oil,
which causes them to clog and swell. Acne can also affect female patients with
polycystic ovarian syndrome and even hormonal issues like excessive androgen
production. Social withdrawal, low self-esteem, and depression with suicidal
thoughts are common in people with acne vulgaris.
Over the forecast period, the
U.S. is anticipated to be the
Global Acne Vulgaris Treatment Market with the highest volume of
acne vulgaris treatment products. A 2015 study that was published in the
British Journal of Dermatology estimated that 9.4% of the world's population
suffered from acne. Additionally, acne is the eighth most common disease in the
world. The biggest market for treatments for acne vulgaris is the United
States. Over $3 billion was spent on treating acne vulgaris in the United
States in 2013, according to a study by the National Institutes of Health
(NIH). According to the American Academy of Dermatology, the number of acne
vulgaris patients aged 25 and older, particularly women, is significantly
increasing in 2014. Furthermore, low awareness regarding the factors causing
acne is another factor leading to increasing prevalence acne vulgaris.
Acne Vulgaris Treatment Market Product types-
·
Medications
o
Benzoyl peroxides
o
Retinoids
o
Systemic and topical Antibiotics
o
Hormonal Agents
o
Others (Salicylic Acid, Azelic, Dapsone, and
Alternative therapy)
·
Devices
·
Laser devices
·
Heat extraction devices
By 2020, India is anticipated to
have the largest population in the 15–25 year age group. As a result, the
market for acne vulgaris treatment products is extremely lucrative.
Additionally, India has a high glycemic index diet, which is anticipated to
help the market grow over the course of the forecast period. Manufacturers are
also concentrating on creating products to treat acne-related scarring.
Scarring is being treated with new surgical and cosmetic methods, such as
laser, chemical peels, and photodynamic therapy. Another factor anticipated to
support the growth of the acne vulgaris treatment market is rising consumer
preference for alternative methods of treating acne vulgaris, such as herbal
therapy (tee tree oil), due to their lack of side effects.
Over the forecast period,
home-based acne treatment equipment like Neutrogena and Revive light therapy
will see significant growth. In order to improve their product offerings and
maintain their market share, major players in the acne vulgaris treatment
market are concentrating on partnering, acquiring, and developing new products.
For instance, the global beauty company L'Oréal signed a contract with Valeant
Pharmaceuticals International, Inc. in 2017 to purchase its portfolio of skin
care brands, which included the anti-acne brand AcneFree, for US$1.3 billion.
Additionally, Novan Inc. announced in November 2017 that it would carry out a
phase three clinical trial for a new anti-acne molecule.
Nitrici, a proprietary nitric
oxide technology from Novan, enables the controlled release of nitric oxide
from chemical entities. This is advantageous because nitric oxide naturally has
the power to regenerate tissue, eliminate invasive microorganisms, prevent
clotting, control inflammation, and even help eliminate cancer cells. A further
agreement to sell its Obagi Medical Products business for US$ 190 million in
cash was signed by Valeant Pharmaceuticals International, Inc. and Haitong
International Zhonghua Finance Acquisition Fund I, L.P. in 2017. The market for
acne treatment products has a significant presence of Obagi Medical Products.
Major Companies Listed are- Allergan plc, GlaxoSmithKline plc,
Valeant Pharmaceutical International Inc., F.Hoffmann-La Roche AG, Mylan, N.V.,
Bayer AG, Janssen Pharma Inc., Galderma Inc., Pfizer Inc., and Novan Inc.
Comments
Post a Comment